EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors
Young Lim Choi, Manabu Soda, Yoshihiro Yamashita et al. · New England Journal of Medicine · 2010
The EML4 (echinoderm microtubule-associated protein-like 4)-ALK (anaplastic lymphoma kinase) fusion-type tyrosine kinase is an oncoprotein found in 4 to 5% of non-small-cell lung cancers, and clinical trials of specific inhibitors of ALK for the treatment of such tumors are currently under way. Here, we report the discovery of two secondary mutations within the kinase domain of EML4-ALK in tumor cells isolated from a patient during the relapse phase of treatment with an ALK inhibitor. Each mutation developed independently in subclones of the tumor and conferred marked resistance to two different ALK inhibitors. (Funded by the Ministry of Health, Labor, and Welfare of Japan, and others.).
Cited by 1,189 works. doi:10.1056/nejmoa1007478 Open-access PDF
Authors
- Young Lim Choi
- Manabu Soda
- Yoshihiro Yamashita
- Toshihide Ueno
- Junpei Takashima
- Takahiro Nakajima
- Yasushi Yatabe
- Kengo Takeuchi
- Toru Hamada
- Hidenori Haruta
- Yuichi Ishikawa
- Hideki Kimura
- Tetsuya Mitsudomi
- Yoshiro Tanio
- Hiroyuki Mano
References
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain
- Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia
- A Tyrosine Kinase Created by Fusion of the PDGFRA and FIP1L1 Genes as a Therapeutic Target of Imatinib in Idiopathic Hypereosinophilic Syndrome
- The development of imatinib as a therapeutic agent for chronic myeloid leukemia
- Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases
- Identification of Novel Isoforms of the EML4-ALK Transforming Gene in Non–Small Cell Lung Cancer